ArticleIranian journal of otorhinolaryngology2025
Change in Voice Quality with Voice Therapy, Injection Laryngoplasty, and Medialization Thyroplasty.
Article in Iranian journal of otorhinolaryngology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In patients with unilateral vocal fold paralysis (UVFP), voice therapy (VT), injection laryngoplasty (IL), and medialization thyroplasty (MT) are reported to produce significant improvement in voice quality (VQ). However, their long-term outcomes have not been sufficiently evaluated. We assessed the improvement in VQ with VT, IL, and MT over 12 months. Materials and Methods: This prospective observational study involved 95 adult patients with UVFP, categorized into three groups: VT (n=55), IL (n=36), and MT (n=4). The VQ was assessed with voice handicap index (VHI), maximum phonation time (MPT), phonatory gap (PG), and breathy voice quality (BVQ) on Day 1, 15, 30, 90, 180, and 360. Results: In the VT group, the decrease in PG, VHI score, and BVQ score was significant from Day 15, 30, and 30, respectively, while MPT increased significantly from Day 15 (p<0.05). In the MT group, similar changes were observed; however, these changes were significant from Day 1 (p<0.05). In both the groups, the lowest PG, VHI score, and BVQ score, and the highest MPT were attained on Day 360. In the IL group, PG, VHI score, and BVQ score decreased significantly, and MPT values increased significantly at every visit (p<0.05). However, PG, VHI score, and BVQ score started increasing and MPT started decreasing from Day 90, 15, 90, and 180, respectively. Conclusion: All treatment modalities improved the VQ significantly, immediately with IL and MT, and gradually with VT. Moreover, the improvement was long-term with VT and MT, and of intermediate duration with IL.
Indexed as
Identifiers
40453159PMC12126205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.